Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Papaverine→

Papaverine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
58-74-2
Molecular formula
C20H21NO4
Molecular weight
339.4 g/mol
Drug class
Benzylisoquinoline alkaloiddirect-acting smooth-muscle relaxant and vasodilator
Mechanism of action
The precise mechanism is not completely established. Papaverine appears to inhibit multiple phosphodiesterase isoenzymes, increase intracellular cyclic nucleotide signalling and may also directly inhibit calcium channels, relaxing vascular and visceral smooth muscle.
Indications / reported uses
  • Treatment of selected smooth-muscle spasm or vasospastic conditions with formulations and routes authorised in the relevant jurisdiction.
  • Intracavernosal use for erectile dysfunction has been described in specialist practice but should not be interpreted as a universal approved indication.

Sources: https://www.ncbi.nlm.nih.gov/mesh/68010208 · https://www.cancer.gov/publications/dictionaries/cancer-drug/def/papaverine-hydrochloride

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Papaverine Environmental Risk Assessment (ERA) (the Papaverine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.